Pilot Projects Program

试点项目计划

• 批准号: 10630581
• 负责人: DAVID E STEC
• 金额: $ 38.75万
• 依托单位: UNIVERSITY OF MISSISSIPPI MED CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-15 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10630581
• 关键词: Affect; American Heart Association; Appointment; Area; Basic Science; Book Chapters; Cardiorenal syndrome; Cardiovascular Diseases; Categories; Centers of Research Excellence; Clinical Research; Clinical Sciences; Communities; Conflict of Interest; Data; Development; Discipline; Education; Eligibility Determination; Equity; Evaluation; Exposure to; Extramural Activities; Faculty; Financial Support; Funding; Goals; Grant; Grant Review; Health; Individual; International; Journals; Medical center; Mentors; Metabolic Diseases; Mississippi; Paper; Phase; Pilot Projects; Population Research; Program Research Project Grants; Publishing; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Proposals; Resources; Review Committee; Scientist; Series; Services; Study Section; Testing; United States; United States National Institutes of Health; Universities; base; career; ethnic diversity; experience; gender diversity; improved; innovation; meetings; member; mid-career faculty; multidisciplinary; next generation; novel; programs; satisfaction; success; translational potential

PILOT PROJECTS PROGRAM SUMMARY/ABSTRACT The Cardiorenal and Metabolic Diseases Research Center (CMDRC) at the University of Mississippi Medical Center (UMMC) developed a highly successful Pilot Projects Program (PPP) during Phases 1 and 2 of COBRE support. Over the past 9 years, the CMDRC PPP has provided funding, mentoring, core services, and enhanced research infrastructure for 24 pilot grant investigators. The success of this program is highlighted by ~$26.92 million dollars in extramural funding obtained by previous PPP awardees as well as 459 papers published in leading journals in the field, 15 book chapters and 286 presentations at international and national meetings. To amplify the research base developed in Phases 1 and 2, the Phase 3 PPP will continue to support innovative research in the areas of cardiorenal and metabolic diseases. The PPP has four specific aims to achieve these goals: 1) To enhance the PPP developed during Phases 1 and 2, with continued emphasis on soliciting and identifying a diverse group of promising investigators whose research focuses on cardiorenal and metabolic diseases for mentoring and funding to expand the critical mass of extramurally funded CMDRC investigators; 2) To provide rigorous ongoing evaluation of the progress of individual PPP awardees and the overall PPP to maximize the impact on the investigators mentored and funded through this program; 3) To facilitate formation of new collaborative, multidisciplinary teams of investigators whose complementary expertise catalyzes the development of translational projects that result in competitive, cutting- edge multi-PI proposals for extramural funding; 4) To increase the critical mass of investigators in cardiorenal and metabolic diseases research at UMMC and to provide mentoring and funding to increase their competiveness for conducting extramurally funded basic, clinical and population research. Thus, the PPP in Phase 3 will continue to provide mentoring as well as financial and developmental support for innovative cardiorenal and metabolic diseases projects to further increase the number and diversity of funded CMDRC researchers.

试点项目计划 摘要/摘要 密西西比医科大学心脏肾脏和代谢性疾病研究中心 中心(UMMC)在Cobre的第一阶段和第二阶段制定了非常成功的试点项目计划(PPP 支持。在过去的9年里，CMDRC PPP提供了资金、指导、核心服务和 加强24名试点赠款调查员的研究基础设施。这项计划的成功主要体现在以下几点 前PPP获奖者获得的2692万美元的外部资金以及459篇论文 在该领域的主要期刊上发表，15本书的章节和在国际和国内的286次演讲 开会。为了扩大在第一阶段和第二阶段发展的研究基础，第三阶段购买力平价将继续 支持心肾和代谢性疾病领域的创新研究。PPP有四个具体的 旨在实现这些目标：1)加强在第一和第二阶段制定的购买力平价，并继续 强调征集和确定各种有前途的调查人员群体，他们的研究重点是 心肾和代谢性疾病的指导和资助，以扩大体外的临界质量 资助CMDRC调查员；2)对个别公私伙伴关系的进展情况提供严格的持续评估 获奖者和整体购买力平价，以最大限度地影响通过以下方式指导和资助的调查人员 方案；3)促进形成新的协作、多学科的调查小组，其 互补的专业知识促进翻译项目的开发，从而产生具有竞争力的、尖端的- EDGE多PI关于外部资金的建议；4)增加心肾研究人员的临界人数 和代谢疾病研究，并提供指导和资金，以增加他们 进行基础、临床和人口研究的外部资助的竞争力。因此，中国的PPP 第三阶段将继续提供指导以及资金和开发支持，以 心肾和代谢性疾病项目，以进一步增加由CMDRC资助的数量和多样性 研究人员。